|
KR101389246B1
(ko)
|
2004-07-15 |
2014-04-24 |
브리스톨-마이어스스퀴브컴파니 |
아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
|
EA016945B1
(ru)
*
|
2005-10-07 |
2012-08-30 |
Экселиксис, Инк. |
ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
|
|
PT2474545T
(pt)
*
|
2005-12-13 |
2017-02-14 |
Incyte Holdings Corp |
Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase
|
|
US7683060B2
(en)
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
CN101594909A
(zh)
*
|
2006-09-07 |
2009-12-02 |
比奥根艾迪克Ma公司 |
用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
|
|
CN101528744A
(zh)
*
|
2006-10-20 |
2009-09-09 |
Irm责任有限公司 |
用于调节c-kit和pdgfr受体的组合物和方法
|
|
MY188335A
(en)
|
2006-11-22 |
2021-11-30 |
Incyte Holdings Corp |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
|
AR067326A1
(es)
*
|
2007-05-11 |
2009-10-07 |
Novartis Ag |
Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
|
|
GEP20125533B
(en)
|
2007-06-13 |
2012-05-25 |
Incyte Corp |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentyl propanenitrile
|
|
FR2918061B1
(fr)
|
2007-06-28 |
2010-10-22 |
Sanofi Aventis |
Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
|
|
EP2300470A2
(en)
*
|
2008-05-19 |
2011-03-30 |
Sepracor Inc. |
Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators
|
|
BRPI0912882A2
(pt)
|
2008-05-21 |
2017-05-16 |
Incyte Corp |
sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
|
|
AR071997A1
(es)
*
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
|
TWI496779B
(zh)
*
|
2008-08-19 |
2015-08-21 |
Array Biopharma Inc |
作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
|
|
US8895550B2
(en)
|
2008-08-19 |
2014-11-25 |
Array Biopharma Inc. |
Triazolopyridine compounds as PIM kinase inhibitors
|
|
US8987251B2
(en)
|
2008-08-19 |
2015-03-24 |
Array Biopharma Inc. |
Triazolopyridine compounds as PIM kinase inhibitors
|
|
US8557809B2
(en)
*
|
2008-08-19 |
2013-10-15 |
Array Biopharma Inc. |
Triazolopyridine compounds as PIM kinase inhibitors
|
|
RS53350B
(sr)
|
2008-09-22 |
2014-10-31 |
Array Biopharma, Inc. |
Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
EP2350071B1
(en)
|
2008-10-22 |
2014-01-08 |
Array Biopharma, Inc. |
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
|
|
CN102458123A
(zh)
|
2009-05-12 |
2012-05-16 |
阿尔巴尼分子研究公司 |
芳基、杂芳基和杂环取代的四氢异喹啉及其用途
|
|
MX2011012369A
(es)
*
|
2009-05-20 |
2012-03-16 |
Cylene Pharmaceuticals Inc |
Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
|
|
WO2010135650A1
(en)
*
|
2009-05-22 |
2010-11-25 |
Incyte Corporation |
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
|
|
HRP20192203T1
(hr)
|
2009-05-22 |
2020-03-06 |
Incyte Holdings Corporation |
3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
TW201113285A
(en)
*
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
EP2525659B1
(en)
*
|
2010-01-19 |
2019-02-27 |
Merck Sharp & Dohme Corp. |
PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
|
|
JP5714030B2
(ja)
|
2010-02-03 |
2015-05-07 |
インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
|
|
AR080151A1
(es)
|
2010-02-09 |
2012-03-14 |
Exelixis Inc |
Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
|
|
PE20130038A1
(es)
|
2010-03-10 |
2013-01-28 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de jak1
|
|
WO2011137155A1
(en)
*
|
2010-04-28 |
2011-11-03 |
Bristol-Myers Squibb Company |
Imidazopyridazinyl compounds and their uses for cancer
|
|
EP2565192B9
(en)
*
|
2010-04-30 |
2015-11-25 |
The University of Tokyo |
Anticancer agent
|
|
PL3205654T3
(pl)
|
2010-05-20 |
2019-08-30 |
Array Biopharma, Inc. |
Związki makrocykliczne jako inhibitory kinazy TRK
|
|
RS54824B1
(sr)
|
2010-05-21 |
2016-10-31 |
Incyte Holdings Corp |
Topikalna formulacija za inhibiciju jak-a
|
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
KR20140019300A
(ko)
|
2010-11-19 |
2014-02-14 |
인사이트 코포레이션 |
Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
|
|
RU2598846C2
(ru)
|
2011-02-25 |
2016-09-27 |
Эррэй Биофарма Инк. |
Триазолопиридиновые соединения как ингибиторы киназы pim
|
|
CA2836203A1
(en)
|
2011-05-17 |
2012-11-22 |
Bayer Intellectual Property Gmbh |
Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
|
|
CN103717604B
(zh)
|
2011-06-01 |
2016-06-01 |
拜耳知识产权有限责任公司 |
取代的氨基咪唑并哒嗪
|
|
EA201490042A1
(ru)
|
2011-06-20 |
2014-10-30 |
Инсайт Корпорейшн |
Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
|
|
HK1197063A1
(en)
|
2011-06-22 |
2015-01-02 |
拜耳知识产权有限责任公司 |
Heterocyclyl aminoimidazopyridazines
|
|
WO2013005041A1
(en)
*
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Tricyclic heterocyclic compounds as kinase inhibitors
|
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
|
EP2742046A1
(en)
*
|
2011-08-12 |
2014-06-18 |
F.Hoffmann-La Roche Ag |
PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA117092C2
(uk)
|
2011-09-06 |
2018-06-25 |
Байєр Інтеллектуал Проперті Гмбх |
Амінозаміщені імідазопіридазини
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
US9320737B2
(en)
|
2011-09-23 |
2016-04-26 |
Bayer Intellectual Property Gmbh |
Substituted imidazopyridazines
|
|
UA113186C2
(xx)
*
|
2011-09-30 |
2016-12-26 |
|
Макроциклічні інгібітори lrrk2 кінази
|
|
KR20140078710A
(ko)
*
|
2011-09-30 |
2014-06-25 |
온코디자인 에스.에이. |
거대고리 flt3 키나제 억제제
|
|
JP6057907B2
(ja)
*
|
2011-10-04 |
2017-01-11 |
株式会社ヤクルト本社 |
チアゾリジン誘導体又はその塩を有効成分とする医薬品
|
|
CA2858685A1
(en)
|
2011-12-12 |
2013-06-20 |
Bayer Intellectual Property Gmbh |
Amino-substituted imidazopyridazines
|
|
ES2663609T3
(es)
|
2012-03-29 |
2018-04-16 |
Bayer Intellectual Property Gmbh |
Imidazopiridazinas amino-sustituidas
|
|
US10280168B2
(en)
*
|
2012-03-30 |
2019-05-07 |
Agency For Science, Technology And Research |
Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
|
|
GB201205669D0
(en)
|
2012-03-30 |
2012-05-16 |
Agency Science Tech & Res |
Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
|
|
EP2834245B1
(en)
*
|
2012-04-04 |
2017-12-13 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazopyridazines
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
TWI585088B
(zh)
*
|
2012-06-04 |
2017-06-01 |
第一三共股份有限公司 |
作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
|
|
EP2872161B1
(en)
|
2012-06-26 |
2020-12-16 |
Del Mar Pharmaceuticals |
Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
|
|
TWI761825B
(zh)
|
2012-11-15 |
2022-04-21 |
美商英塞特控股公司 |
盧梭利替尼之緩釋性劑型
|
|
EP2920181B1
(en)
|
2012-11-16 |
2019-01-09 |
University Health Network |
Pyrazolopyrimidine compounds
|
|
RS56720B1
(sr)
|
2012-11-19 |
2018-03-30 |
Novartis Ag |
Jedinjenja i kompozicije za lečenje parazitskih oboljenja
|
|
EP2920176B1
(en)
|
2012-11-19 |
2017-09-13 |
Bayer Pharma Aktiengesellschaft |
Aminoimidazopyridazines as mknk1 kinase inhibitors
|
|
US8871754B2
(en)
|
2012-11-19 |
2014-10-28 |
Irm Llc |
Compounds and compositions for the treatment of parasitic diseases
|
|
EP2943485B1
(en)
|
2013-01-14 |
2017-09-20 |
Incyte Holdings Corporation |
Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
|
|
PE20191245A1
(es)
|
2013-01-15 |
2019-09-18 |
Incyte Holdings Corp |
Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
|
|
CN105008363A
(zh)
|
2013-01-30 |
2015-10-28 |
拜耳医药股份公司 |
作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪
|
|
HK1212699A1
(zh)
|
2013-02-20 |
2016-06-17 |
拜耳医药股份公司 |
作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物
|
|
BR122021015061B1
(pt)
|
2013-03-06 |
2022-10-18 |
Incyte Holdings Corporation |
Processos e intermediários para preparar um inibidor de jak
|
|
JP2016510764A
(ja)
|
2013-03-07 |
2016-04-11 |
カリフィア バイオ, インク.Califia Bio, Inc. |
混合系キナーゼ阻害剤および治療法
|
|
SG11201507493SA
(en)
*
|
2013-03-15 |
2015-10-29 |
Oncodesign Sa |
Macrocyclic salt-inducible kinase inhibitors
|
|
JP6023630B2
(ja)
*
|
2013-04-03 |
2016-11-09 |
株式会社ヤクルト本社 |
チアゾロン誘導体
|
|
AU2014251038A1
(en)
|
2013-04-08 |
2015-11-26 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
MX372671B
(es)
*
|
2013-07-19 |
2020-04-23 |
Onyx Therapeutics Inc |
Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
|
|
WO2015021153A1
(en)
|
2013-08-07 |
2015-02-12 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
|
CN105658653A
(zh)
|
2013-08-23 |
2016-06-08 |
因赛特公司 |
可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
|
|
AR097543A1
(es)
*
|
2013-09-06 |
2016-03-23 |
Lexicon Pharmaceuticals Inc |
COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
|
|
CN105899512A
(zh)
|
2014-01-09 |
2016-08-24 |
拜耳医药股份公司 |
可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪
|
|
CN103864800A
(zh)
*
|
2014-04-03 |
2014-06-18 |
定陶县友帮化工有限公司 |
6-氯咪唑并[1,2-b]哒嗪的合成方法
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
GB201410817D0
(en)
*
|
2014-06-17 |
2014-07-30 |
Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D |
Therapeutic agents
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
WO2016010897A1
(en)
|
2014-07-14 |
2016-01-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
|
|
AU2015316799B2
(en)
*
|
2014-09-17 |
2019-07-11 |
Oncodesign Precision Medicine (OPM) |
Macrocyclic RIP2 kinase inhibitors
|
|
CN107428760B
(zh)
|
2014-11-16 |
2021-04-27 |
阵列生物制药公司 |
(s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型
|
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
|
AR105967A1
(es)
|
2015-09-09 |
2017-11-29 |
Incyte Corp |
Sales de un inhibidor de pim quinasa
|
|
US9920032B2
(en)
|
2015-10-02 |
2018-03-20 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
BR112018008357A2
(en)
|
2015-10-26 |
2018-11-27 |
Loxo Oncology, Inc. |
dot mutations in trk inhibitor resistant cancer and related methods
|
|
US10525047B2
(en)
*
|
2016-03-25 |
2020-01-07 |
University Of Maryland, Baltimore County |
PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers
|
|
RS65988B1
(sr)
|
2016-04-04 |
2024-10-31 |
Loxo Oncology Inc |
Postupak lečenja pedijatrijskih karcinoma
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
FI3439662T3
(fi)
|
2016-04-04 |
2024-09-04 |
Loxo Oncology Inc |
(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
|
|
HRP20201984T1
(hr)
|
2016-05-18 |
2021-04-16 |
Loxo Oncology, Inc. |
Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
TWI778050B
(zh)
|
2017-04-21 |
2022-09-21 |
美商醫肯納腫瘤學公司 |
吲哚ahr抑制劑及其用途
|
|
US11344553B2
(en)
*
|
2017-08-11 |
2022-05-31 |
Teligene Ltd. |
Substituted pyrazolopyrimidines useful as kinases inhibitors
|
|
SG11202001310SA
(en)
|
2017-08-17 |
2020-03-30 |
Ikena Oncology Inc |
Ahr inhibitors and uses thereof
|
|
WO2019090205A1
(en)
|
2017-11-06 |
2019-05-09 |
Snap Bio, Inc. |
Pim kinase inhibitor compositions, methods, and uses thereof
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
WO2019152374A1
(en)
|
2018-01-30 |
2019-08-08 |
Incyte Corporation |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
PL3773593T3
(pl)
|
2018-03-30 |
2024-09-02 |
Incyte Corporation |
Leczenie ropnego zapalenia gruczołów potowych z zastosowaniem inhibitorów jak
|
|
JP2021521170A
(ja)
|
2018-04-13 |
2021-08-26 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
|
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
EP4061367A1
(en)
|
2019-11-22 |
2022-09-28 |
Incyte Corporation |
Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
|
|
ES3028099T3
(en)
|
2019-11-26 |
2025-06-18 |
Ikena Oncology Inc |
Polymorphic carbazole derivatives and uses thereof
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US20230355617A1
(en)
*
|
2020-09-14 |
2023-11-09 |
The University Of Sussex |
Small molecule inhibitors of lemur tyrosine kinase 3
|
|
EP4267137A4
(en)
*
|
2020-12-22 |
2024-11-06 |
Enliven Inc. |
HETEROARYL-LACTAM-FUSION PYRIMIDINE DERIVATIVES AS ERBB2 INHIBITORS
|
|
CN115991706A
(zh)
*
|
2021-02-08 |
2023-04-21 |
杭州邦顺制药有限公司 |
Pim激酶抑制剂
|
|
EP4413000A1
(en)
*
|
2021-10-04 |
2024-08-14 |
FoRx Therapeutics AG |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
|
CN116262753A
(zh)
*
|
2021-12-13 |
2023-06-16 |
杭州邦顺制药有限公司 |
一种新颖的pim激酶抑制剂
|
|
WO2024097653A1
(en)
|
2022-10-31 |
2024-05-10 |
Sumitomo Pharma America, Inc. |
Pim1 inhibitor for treating myeloproliferative neoplasms
|
|
EP4434972A1
(en)
*
|
2023-03-22 |
2024-09-25 |
Eberhard-Karls-Universität Tübingen |
Atm kinase inhibitors
|
|
WO2025231112A1
(en)
*
|
2024-05-01 |
2025-11-06 |
Nimbus Salacia, Inc. |
Sik2 modulators and uses thereof
|
|
WO2025231117A1
(en)
*
|
2024-05-01 |
2025-11-06 |
Nimbus Salacia, Inc. |
Sik2 modulators and uses thereof
|